Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

Current Medical Research and Opinion
Avraham KarasikPeter P Stein

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antihyperglycemic agents that enhance the body's ability to regulate blood glucose by increasing the active levels of incretins, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). There are numerous DPP-4 inhibitors in development with sitagliptin as the first approved agent for the treatment of patients with type 2 diabetes. The purpose of this review is to provide an overview of the clinical trial results with sitagliptin. Clinical trials published between January 2005 (first sitagliptin publication) and November 2007 were included in this review. Medline was searched using the search terms: MK-0431 or sitagliptin. Sitagliptin, an oral, once-daily, and highly selective DPP-4 inhibitor, has been evaluated in clinical trials as monotherapy, as add-on therapy, or as initial combination therapy with metformin. Sitagliptin provided effective fasting and postprandial glycemic control in a wide range of patients with type 2 diabetes. Markers of beta-cell function (HOMA-beta and proinsulin/insulin ratio) were improved with sitagliptin treatment. In these clinical trials, sitagliptin was generally well tolerated with an overall incidence...Continue Reading

References

Apr 1, 1993·Digestive Diseases and Sciences·A WettergrenJ J Holst
Mar 21, 1998·The Journal of Clinical Investigation·A FlintJ J Holst
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Silvio E Inzucchi
May 6, 2004·The Journal of Clinical Endocrinology and Metabolism·Bo AhrénAnja Schweizer
Aug 28, 2004·Expert Opinion on Investigational Drugs·Carolyn F DeaconJens J Holst
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Feb 11, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Orville G KoltermanAlain D Baron
Mar 7, 2006·Cell Metabolism·Daniel J Drucker
Jul 11, 2006·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·R E PratleyD Holmes
Nov 18, 2006·International Journal of Clinical Practice·B Gallwitz
Jan 16, 2007·Diabetes Research and Clinical Practice·F Xavier Pi-SunyerSylvie Dejager

❮ Previous
Next ❯

Citations

Feb 5, 2010·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Baptist Gallwitz
Sep 19, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Thomas RauchTim Heise
Oct 12, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Miyako Kishimoto, Mitsuhiko Noda
Jun 24, 2011·Chemical Reviews·Jonathan Z Long, Benjamin F Cravatt
Oct 17, 2009·American Journal of Therapeutics·Zafar H Israili
Jun 4, 2008·Diabetes, Obesity & Metabolism·J C N ChanD Williams-Herman
Jan 15, 2010·Diabetes, Obesity & Metabolism·P AschnerUNKNOWN Sitagliptin Study 049 Group
Jul 13, 2011·Experimental Diabetes Research·Ilaria DicembriniCarlo Maria Rotella
Sep 17, 2013·Drug Design, Development and Therapy·Vinay S Eligar, Stephen C Bain
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Shannon A MillerJ Roger Accardi
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Radha AndukuriMarc Rendell
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Baptist Gallwitz
May 5, 2009·International Journal of Food Sciences and Nutrition·Tsuneyuki OkuSadako Nakamura
Feb 3, 2012·Expert Opinion on Pharmacotherapy·Marc RendellRadha Andukuri
Jun 2, 2012·Expert Opinion on Drug Discovery·Kishore Vl Parsa, Manojit Pal
Dec 3, 2008·Expert Opinion on Emerging Drugs·Bo Ahrén
Dec 10, 2014·Expert Opinion on Drug Safety·Sri Harsha Tella, Marc S Rendell
Aug 21, 2009·Current Medical Research and Opinion·M AlbaB J Goldstein
Feb 13, 2010·The Canadian Journal of Cardiology·Paul E SzmitkoSubodh Verma
Sep 11, 2010·Biochemical and Biophysical Research Communications·Wataru TakasawaChikao Morimoto
Apr 23, 2010·Journal of the American Society of Hypertension : JASH·Kiwon BanMansoor Husain
Jun 12, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M MonamiE Mannucci
Dec 23, 2008·Diabetes Research and Clinical Practice·Viswanathan MohanKeith D Kaufman
Jan 27, 2009·Pharmacology & Therapeutics·M ReimannS R Bornstein
Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Friederike RemmChristoph Brenner
Jan 29, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Juan C Arjona FerreiraBarry J Goldstein
May 21, 2014·Journal of Diabetes Investigation·Naoko TajimaJuan Camilo Arjona Ferreira
Feb 28, 2013·Journal of Clinical Pharmacy and Therapeutics·Susan A Cornell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.